Familial Hypercholesterolemia Clinical Trial
Official title:
Atlantic Lipid Lowering Treatment Optimization Program (ALLTOP): A Comprehensive Approach to the Treatment of Familial Hypercholesterolemia and Complex Dyslipidemias
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.
This study will screen patients with LDL-C >160 mg/dL and with evidence of familial hypertension, reach out (using secure chat) to the attending practitioner of such patients and inform the practitioner of our comprehensive services to address FH. A study team member will inform the practitioner that one of the study team plans to reach out to their patient to inform the patient of the study. Unless one of the study team receives notification by the practitioner that they want to opt out of this service for their patients, and do not want further interaction, the patient will be informed of the study and the consent process. The research question is: Will an innovative comprehensive outreach approach, in conjunction with the primary care provider, reduce LDL-C levels in individuals with familial hypercholesteremia below individual baseline values, ideally at a level at or below 100 mg/dL. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05284513 -
Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)
|
N/A | |
Enrolling by invitation |
NCT05271305 -
Pilot Study for a National Screening for Familial Hypercholesterolemia
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Not yet recruiting |
NCT00924339 -
Soy Food Intervention Trial
|
N/A | |
Withdrawn |
NCT00751608 -
Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients
|
Phase 2 | |
Terminated |
NCT00079846 -
Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy
|
Phase 2 | |
Completed |
NCT02624869 -
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
|
Phase 3 | |
Recruiting |
NCT05758779 -
The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial
|
N/A | |
Enrolling by invitation |
NCT04929457 -
Evaluation of a Digiphysical Screening Method to Identify and Diagnose Familial Hypercholesterolemia
|
||
Not yet recruiting |
NCT04455581 -
A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia
|
Phase 2 | |
Recruiting |
NCT04101149 -
Genetic Causes of Familial Hypercholesterolemia
|
||
Completed |
NCT00943306 -
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Completed |
NCT02462655 -
Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia
|
N/A | |
Terminated |
NCT00079859 -
Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
|
Phase 2 | |
Recruiting |
NCT05066932 -
Advanced Lipoproptein Profiling and Cardiovascular Risk Stratification in Familial Hypercholesterolemia
|
||
Not yet recruiting |
NCT04958629 -
A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population
|
||
Completed |
NCT02709850 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia
|
Phase 1 | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Terminated |
NCT02013713 -
French Observatory of Familial Hypercholesterolemia in Cardiology
|
||
Recruiting |
NCT02009345 -
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
|